GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Bass’ New Buy – ZIOPHARM Oncology Inc.

May 16, 2013 | About:
Holly LaFon

Holly LaFon

272 followers
The founder of Hayman Advisors Kyle Bass made a fortune during the sub-prime crisis, and today he does not like Japan and likes structured mortgages, housing, gold and U.S. stocks. His U.S. portfolio contains eight stocks – one of them new. With seven stocks sold out, his portfolio had 47% quarter-over-quarter turnover and a value of $165 million.

The new position is a company called ZIOPHARM Oncology Inc. (ZIOP). Bass bought 316,987 shares at an average price of $4. He also bought and sold a smaller parcel of shares of the company in the first and second quarter of 2012.



ZIOPHARM Oncology Inc. is a Delaware Corporation. It is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. The drug in the latest stage is Palifosfamide (ZIO-201) which is a type of drug called alkylating agents that binds to cancer cell DNA to halt tumor growth. It is currently in Phase 3 studies.

Ziopharm Oncology Inc. has a market cap of $144.6 million; its shares were traded around $1.76 with and P/S ratio of 176.50.

Other Gurus who bought the stock in the fourth quarter include: Jean-Marie Eveillard, Paul Tudor Jones and Steven Cohen.

See Kyle Bassportfolio here. Also check out the Undervalued Stocks, Top Growth Companies and High Yield stocks of Kyle Bass.


Rating: 2.3/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK